Abstract:Avian influenza A(H6N1) virus is one of the most common viruses isolated from migrating birds and domestic poultry in many countries. The first and only known case of human infection by H6N1 virus in the world was reported in Taiwan in 2013. This led to concern that H6N1 virus may cause a threat to public health. In this study, we engineered a recombinant H6N1 virus-like particle (VLP) and investigated its vaccine effectiveness compared to the traditional egg-based whole inactivated virus (WIV) vaccine. The H6N1-VLPs exhibited similar morphology and functional characteristics to influenza viruses. Prime-boost intramuscular immunization in mice with unadjuvanted H6N1-VLPs were highly immunogenic and induced long-lasting antibody immunity. The functional activity of the VLP-elicited IgG antibodies was proved by in vitro seroprotective hemagglutination inhibition and microneutralization titers against the homologous human H6N1 virus, as well as in vivo viral challenge analyses which showed H6N1-VLP immunization significantly reduced viral load in the lung, and protected against human H6N1 virus infection. Of particular note, the H6N1-VLPs but not the H6N1-WIVs were able to confer cross-reactive humoral immunity; antibodies induced by H6N1-VLP vaccine robustly inhibited the hemagglutination activities and in vitro replication of distantly-related heterologous avian H6N1 viruses. Furthermore, the H6N1-VLPs were found to elicit significantly greater anti-HA2 antibody responses in immunized mice than H6N1-WIVs. Collectively, we demonstrated for the first time a novel H6N1-VLP vaccine that effectively provides broadly protective immunity against both human and avian H6N1 viruses. These results, which uncover the underlying mechanisms for induction of wide-range immunity against influenza viruses, may be useful for future influenza vaccine development.

Induction of Long-Term Protective Immune Responses by Influenza H5N1 Virus-Like Particles

Virus-Like Particle Vaccine Induces Protective Immunity Against Homologous and Heterologous Strains of Influenza Virus

Protective immunity against H5N1 influenza virus by a single dose vaccination with virus-like particles.

Virus-like Particle Vaccine Comprised of the HA, NA, and M1 Proteins of an Avian Isolated H5N1 Influenza Virus Induces Protective Immunity Against Homologous and Heterologous Strains in Mice.

Protection Induced by Early Stage Vaccination with Pandemic Influenza Virus-Like Particles.

Virus-Like Particle Vaccine Containing Hemagglutinin Confers Protection Against 2009 H1N1 Pandemic Influenza

Immune Correlates of Protection Induced by Virus-Like Particles Containing 2009 H1N1 Pandemic Influenza HA, NA or M1 Proteins

A Pandemic H1N1 Influenza Virus-Like Particle Vaccine Induces Cross-Protection in Mice

Inclusion of Membrane-Anchored LTB or Flagellin Protein in H5N1 Virus-Like Particles Enhances Protective Responses Following Intramuscular and Oral Immunization of Mice.

Induction of protective immune response to intranasal administration of influenza virus‐like particles in a mouse model

Microneedle Delivery of H5n1 Influenza Virus-Like Particles to the Skin Induces Long-Lasting B- and T-Cell Responses in Mice

Intramuscular and Intranasal Immunization with an H7N9 Influenza Virus-Like Particle Vaccine Protects Mice Against Lethal Influenza Virus Challenge.

H5N1 Influenza Virus-Like Particle Vaccine Protects Mice from Heterologous Virus Challenge Better Than Whole Inactivated Virus.

Preliminary Study on H1N1 Virus-Like Particle Vaccine

Kinetics of Immune Responses to Influenza Virus-Like Particles and Dose-Dependence of Protection with A Single Vaccination

Incorporation of Conserved Nucleoprotein into Influenza Virus-Like Particles Could Provoke a Broad Protective Immune Response in BALB/c Mice and Chickens

Vaccinia virus-based multivalent H5N1 avian influenza vaccines adjuvanted with IL-15 confer sterile cross-clade protection in mice

A novel H6N1 virus-like particle vaccine induces long-lasting cross-clade antibody immunity against human and avian H6N1 viruses

Baculovirus-derived influenza virus-like particle confers complete protection against lethal H7N9 avian influenza virus challenge in chickens and mice

Neuraminidase in Virus-like Particles Contributes to the Protection Against High Dose of Avian Influenza Virus Challenge Infection.

A Recombinant Protein Containing Highly Conserved Hemagglutinin Residues 81-122 of Influenza H5N1 Induces Strong Humoral and Mucosal Immune Responses.